CellaVision AB (CHIX:CEVIS) Marketable Securities: kr0.0 Mil (As of Mar. 2026)


CHIX:CEVIS CellaVision AB CHIX:CEVIS
95 GF Score
Price kr160.20
GF Value kr231.79
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Marketable Securities?

CellaVision AB CHIX:CEVIS 95 Marketable Securities is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:CEVIS with a GF Score™ of 95/100 and a GF Value™ of kr231.79. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. CellaVision AB's Marketable Securities for the quarter that ended in Mar. 2026 was kr0.0 Mil.

CellaVision AB  (CHIX:CEVIs) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

CellaVision AB Marketable Securities Related Terms

CellaVision AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Marketable Securities Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:CEVIS
95GF Score
CellaVision AB CHIX:CEVIS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.0 Mil mean?
CellaVision AB (CHIX:CEVIS) has a Marketable Securities of kr0.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Marketable Securities too high?
CellaVision AB's current Marketable Securities is kr0.0 Mil. Overall, CellaVision AB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Marketable Securities compare to ABT and SYK?
CellaVision AB's Marketable Securities of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CellaVision AB and its competitors. CellaVision AB's current Marketable Securities is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Marketable Securities of kr0.0 Mil. The stock's GF Value™ is kr231.79, compared to a current price of kr160.20 — trading 30.9% below its estimated fair value. The current Marketable Securities is kr0.0 Mil. CellaVision AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Marketable Securities is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of kr160.20 is trading 30.9% below its estimated GF Value™ of kr231.79.

Key valuation signals for CHIX:CEVIS:

  • Marketable Securities: kr0.0 Mil
  • GF Value™: kr231.79 vs. price of kr160.20 (30.9% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
95GF Score

Get the complete analysis for CHIX:CEVIS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr160.20
Price
kr231.79
GF Value